Imp1 is normally expressed during embryonic development but becomes silenced postnatally, with aberrant re-expression in multiple cancers driving tumor progression (Degrauwe et al., 2016; Hamilton et al., 2013; Zhu et al., 2023). The gene discussed is IGF2BP1; the disease is neoplasm.